P

Protalix BioTherapeutics
D

PLX

1.51500
USD
-0.04
(-2.57%)
مغلق
حجم التداول
3,408
الربح لكل سهم
0
العائد الربحي
-
P/E
30
حجم السوق
120,604,779
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
AMZN
AMZN
-0.780
(-0.34%)
231.450 USD
A
ARWR
-0.520
(-3.20%)
15.740 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
NFLX
NFLX
-0.27
(-0.02%)
1,180.72 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
V
VKTX
0.960
(2.87%)
34.420 USD
المزيد
الأخبار المقالات

العنوان: Protalix BioTherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.